Abera Bioscience AB (NGM:ABERA)

Abera Bioscience AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Other Revenue	11.89	14.63	2.52	1.79	1.18
Revenue	11.89	14.63	2.52	1.79	1.18
Revenue Growth (YoY)	-18.74%	479.60%	41.18%	51.78%	55.92%
Gross Profit	11.89	14.63	2.52	1.79	1.18
Selling, General & Admin	22.12	15.72	19.35	21.19	10.34
Other Operating Expenses	0.16	0.18	0.09	0.05	0.02
Operating Expenses	22.47	15.97	19.45	21.24	10.35
Operating Income	-10.58	-1.34	-16.92	-19.45	-9.18
Interest Expense	-	-0	-	-	-0
Interest & Investment Income	0.13	0.02	0.08	0.01	-
Currency Exchange Gain (Loss)	-	0.22	0.12	0.06	0.01
Other Non Operating Income (Expenses)	-	-0	-0	-	-
Pretax Income	-10.45	-1.1	-16.72	-19.38	-9.17
Net Income	-10.45	-1.1	-16.72	-19.38	-9.17
Net Income to Common	-10.45	-1.1	-16.72	-19.38	-9.17
Shares Outstanding (Basic)	17	16	13	12	10
Shares Outstanding (Diluted)	17	16	13	12	10
Shares Change (YoY)	5.59%	18.42%	13.66%	14.64%	45.39%
EPS (Basic)	-0.63	-0.07	-1.26	-1.66	-0.90
EPS (Diluted)	-0.63	-0.07	-1.26	-1.66	-0.90
Free Cash Flow	-3.68	-1.33	-17.71	-19.69	-9.68
Free Cash Flow Per Share	-0.22	-0.09	-1.33	-1.69	-0.95
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-88.99%	-9.15%	-670.48%	-1088.19%	-779.01%
Profit Margin	-87.94%	-7.52%	-662.44%	-1084.01%	-778.09%
Free Cash Flow Margin	-30.99%	-9.09%	-701.70%	-1101.46%	-821.76%
EBITDA	-10.39	-1.28	-	-	-
EBITDA Margin	-87.38%	-8.73%	-	-	-
D&A For EBITDA	0.19	0.06	-	-	-
EBIT	-10.58	-1.34	-16.92	-19.45	-9.18
EBIT Margin	-88.99%	-9.15%	-	-	-
Revenue as Reported	11.89	14.85	2.65	1.85	1.19

Source: S&P Global Market Intelligence. Standard template. Financial Sources.